Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Preparing for Alzheimer’s test results means taking three concrete steps before you get tested: understand what the blood tests can and cannot tell you, gather your family’s questions and concerns, and establish a plan for what to do with the results. Families should know that new FDA-cleared blood tests like the Lumipulse G test and Labcorp Elecsys pTau-181 test can detect Alzheimer’s disease pathology with high accuracy, but these results are not the same as a diagnosis—a positive biomarker result requires clinical context and may mean further evaluation is needed. For example, if your mother shows signs of memory loss and a blood test indicates Alzheimer’s pathology, this might prompt an MRI or specialist consultation rather than an immediate diagnosis, so your family needs to be prepared for that intermediate stage of uncertainty.
The stakes are significant: approximately 1 in 9 people age 65 and older have Alzheimer’s disease, and about two-thirds of those living with it are women. With the national cost of care projected to reach $409 billion in 2026, families need to understand testing outcomes well enough to make informed decisions about medical care, finances, legal documents, and long-term planning. This article walks you through what families need to do before, during, and after Alzheimer’s testing.
Table of Contents
- What You Need to Know About Modern Alzheimer’s Blood Tests
- Understanding Your Test Results and What They Actually Mean
- Preparing Your Family Emotionally and Practically for the Testing Journey
- Financial and Legal Planning Before You Get Test Results
- Common Family Concerns About Alzheimer’s Blood Testing
- Creating an Action Plan With Your Healthcare Team
- Preparing for the Months Ahead After Results Arrive
- Conclusion
What You Need to Know About Modern Alzheimer’s Blood Tests
The two main FDA-cleared blood tests available in 2025-2026 have fundamentally changed how doctors screen for Alzheimer’s disease pathology. The Lumipulse G test shows 92% concordance with amyloid PET imaging for positive results and 97% for negative results, meaning it’s highly accurate at detecting the physical pathology associated with Alzheimer’s. The Labcorp Elecsys pTau-181 test offers 97.9% negative predictive value, which means if you test negative, there’s a very high likelihood you don’t have Alzheimer’s pathology. Both tests can be ordered in primary care settings, eliminating the need for an expensive specialist visit just to access testing. However, one important limitation: about 20% of Lumipulse G results fall into an indeterminate range that requires further evaluation.
This means your family could get results that aren’t clearly positive or negative, requiring additional imaging or specialist consultations. Before testing, families should ask their healthcare provider: “If my result is indeterminate, what is the next step?” and “How much will that step cost?” This ambiguity zone is where many families feel most anxious, so preparing emotionally for this possibility matters as much as preparing logistically. The key insight from current research is that a positive biomarker alone does not mean a person has Alzheimer’s disease. A 2026 clinical update from Los Altos Neurology emphasizes that layered evaluation should first rule out reversible or alternate causes of cognitive change—things like vitamin B12 deficiency, thyroid problems, sleep apnea, or depression can mimic cognitive symptoms but are treatable. Your family should insist that your healthcare provider rule out these causes before concluding that a positive blood test equals Alzheimer’s disease.
How to Prepare for Your Test Results and What They Mean
When you receive Alzheimer’s blood test results, interpreting them correctly is crucial to making sound decisions. A positive result indicates the presence of Alzheimer’s pathology—specifically, amyloid-beta or tau proteins—but it doesn’t automatically mean someone has cognitive impairment today or will develop it soon. In fact, research shows that some cognitively normal people have these biomarkers without symptoms, sometimes years before symptoms appear. This is why your doctor will place the blood test result within a broader clinical picture that includes your cognitive symptoms, age, family history, medication review, and other testing. A negative result carries different weight. The 97.9% negative predictive value of the pTau-181 test means that if you test negative and you’re experiencing cognitive symptoms, your symptoms are likely caused by something other than Alzheimer’s pathology.
This is valuable information because it redirects your healthcare team to investigate other causes. For example, if your father is having memory problems, tests negative for Alzheimer’s biomarkers, and takes three medications that interact with cognition, your doctor can confidently say the memory loss is likely medication-related, not Alzheimer’s—and you might solve the problem by changing medications instead of pursuing dementia-specific treatment. An indeterminate result—falling in that gray zone for 20% of Lumipulse tests—means your healthcare provider will likely recommend advanced imaging. An MRI can look at the structure of your brain, checking for shrinkage in memory-related regions or evidence of strokes. A PET scan can visualize where amyloid or tau is accumulating. These tests cost more and take longer, but they give your doctor the visual evidence needed to either confirm Alzheimer’s pathology or identify an alternative explanation for cognitive symptoms. Your family should budget time and money for this possibility before testing begins.
Preparing Your Family Emotionally and Practically for the Testing Journey
Receiving an Alzheimer’s diagnosis or even learning that biomarkers are present triggers a range of emotions in families, and preparation starts well before test results arrive. Research shows that family members often experience fear, anger, relief, or denial when facing serious illness news; denial is actually a common protective response that helps people process overwhelming information gradually. Rather than fighting these reactions, smart families anticipate them and plan how to support each other. Before testing, have a family conversation about what you would do if results come back positive, indeterminate, or negative. Ask yourselves: “What actions would we take in each scenario?” and “How will we tell other family members?” A practical example: if your mother tests positive for Alzheimer’s pathology, would you tell your siblings immediately, or would you wait to discuss it with a neurologist first? Would you tell your children? This conversation prevents hasty decisions made in the emotional moment after results arrive.
The Alzheimer’s Association recommends choosing a calm, private moment to discuss results, allowing time for emotional readiness before sharing news. Professional support during this process is important. The psychological impact of an Alzheimer’s diagnosis includes not just grief about the disease itself but also anxiety about the unknown timeline and care needs ahead. Many families benefit from counseling that addresses these disease-specific concerns and helps with care planning. Additionally, family members should consider dividing future caregiving activities among themselves to reduce stress on any single person—this is a logistics conversation best held before crises demand immediate care decisions.
Financial and Legal Planning Before You Get Test Results
This might sound premature, but the best time to handle financial and legal planning is before or immediately after test results, while the person with cognitive concerns can still participate in decisions. The Alzheimer’s Association reports that the total lifetime cost of care for a person with dementia is an estimated $405,262 (in 2024 dollars), and shockingly, 70% of these costs are borne by unpaid family caregivers. Without proper planning, families absorb enormous financial and emotional burdens that proper legal structures could have prevented. Key legal documents to create include a will, durable power of attorney for finances (allowing someone to handle financial decisions if you become incapacitated), a living trust (which avoids probate and keeps financial matters private), a healthcare power of attorney (designating who makes medical decisions), and a living will or advance directive (outlining your preferences for end-of-life care).
Timing matters enormously: if you wait until a person has progressed to moderate or advanced dementia, they may no longer have the legal capacity to sign these documents or make coherent decisions about their wishes. The window for this is usually while someone is still cognitively intact but has received a diagnosis or positive biomarker results that signal the need for planning. For families without attorney resources, free or low-cost legal assistance is available through state legal aid offices, Area Agencies on Aging, state bar associations, and nonprofit organizations focused on elder care. Since the national cost of Alzheimer’s care is projected to reach $409 billion in 2026 with out-of-pocket spending at $103 billion, families need to explore whether private payment, long-term care insurance, Medicaid, or a combination approach makes sense for their situation. A financial advisor who specializes in elder care can help model these options before a crisis forces expensive emergency decisions.
Common Family Concerns About Alzheimer’s Blood Testing
One major concern that emerges from research is the fear of false positives—families worry that a positive biomarker result will cause anxiety and trigger unnecessary medical interventions if the person never actually develops symptoms. While this is a legitimate concern, the counter-argument is that early detection allows families to pursue preventive strategies now: research increasingly supports lifestyle interventions (exercise, cognitive activity, Mediterranean diet, sleep, social engagement) that may slow cognitive decline even in people with biomarkers present. A false positive, then, becomes an opportunity to optimize health rather than a purely harmful outcome. The flip side is false-negative anxiety: what if someone tests negative, gets reassured, and then develops cognitive symptoms months or years later? The 97.9% negative predictive value of pTau-181 testing is very high, but it’s not 100%.
A negative test should prompt annual or biennial re-screening if cognitive symptoms develop or worsen, rather than a permanent “all clear” assumption. Families should ask their doctor: “If I test negative today but develop memory problems later, when should I be retested?” This creates a safety net rather than a false sense of permanent reassurance. Another concern is privacy and genetic discrimination. Alzheimer’s biomarker testing reveals information about your brain’s future risk that some people worry could affect insurance or employment. While the Genetic Information Nondiscrimination Act (GINA) provides some protections for genetic testing information, it’s worth discussing privacy concerns with your healthcare provider and understanding what happens to your test results—who has access, how long they’re stored, and whether they can be sold for research.
Creating an Action Plan With Your Healthcare Team
Before your test appointment, sit down with your healthcare provider to map out exactly what will happen if results fall into different categories. Ask: “If results are positive, what is the next step?” (Is it an MRI? A neurology referral? A cognitive test?). “How much will that step cost?” “When would you recommend we do it?” “What lifestyle changes would you suggest regardless of results?” Having this conversation in advance prevents scrambling after results arrive. Request that your doctor schedule a dedicated appointment to discuss results in a calm setting—not a rushed phone call while you’re at work or a terse email.
The Alzheimer’s Association recommends that diagnosis disclosure should include psychological counseling addressing disease-specific aspects and care planning, not just a medical explanation. During that results discussion appointment, bring a notebook, a trusted family member or friend, and your written questions. Many people find they forget half of what a doctor says when they’re emotionally activated, so take notes or ask if you can record the conversation. Ask your doctor to explain what the results mean for your daily life right now versus future risk, and what evidence supports any treatment recommendations they’re making.
Preparing for the Months Ahead After Results Arrive
The months immediately following Alzheimer’s diagnosis or positive biomarker results are when families make critical decisions about medical care, finances, and lifestyle. National statistics show that 7.4 million Americans age 65 and older are living with Alzheimer’s in 2026, and researchers project this number could increase to 13.8 million by 2060 without medical breakthroughs. This sobering context underscores why early planning matters: the systems and decisions you put in place now will shape how your family navigates years of care ahead.
Lifestyle interventions gain importance at this stage. Even before a formal treatment plan is recommended, families with positive biomarker results should prioritize regular physical exercise (which consistently delays cognitive decline), cognitive activity (learning new skills, puzzles, reading), social engagement (which buffers against depression and cognitive loss), Mediterranean-style eating, quality sleep, and management of cardiovascular and metabolic health. These are not costly interventions, but they require commitment and family support to sustain. When one family member is making these lifestyle shifts, other family members participating in the changes creates mutual accountability and improves adherence.
Conclusion
Preparing families for Alzheimer’s test results is not just about understanding blood test accuracy or decoding what biomarkers mean—it’s about equipping yourself emotionally, financially, and legally for whatever comes next. The first step is having a clear conversation with your healthcare provider about what will happen before, during, and after testing. The second step is gathering your family to discuss how you’ll respond to different outcomes and what values will guide your care decisions.
The third step is handling financial and legal planning while the person at risk can still participate in decisions. The good news is that testing options have improved dramatically, and even if results are positive or indeterminate, modern medicine offers more information and intervention options than ever before. What matters now is moving forward with eyes open, realistic expectations, and a plan. Whether results come back positive, negative, or indeterminate, your family is better prepared for what comes next than families who avoid testing altogether.
You Might Also Like
- How One Caregiver Story Can Help Other Alzheimer’s Families
- Could Alzheimer’s Walks Help Families Feel Less Alone?
- What Families Should Know About Experimental NeuroEPO Research
Related reading
- could Lifestyle Changes Delay Alzheimer’s Onset
- why Prevention Research Is Hard to Prove
- what Sleep, Diet, Weight, and Heart Health Have in Common
- why Alzheimer’s Prevention Needs Long-Term Thinking
- can Exercise Influence Alzheimer’s Risk
For more on this topic, see Alzheimer’s Association — medical tests.
